SCANDION ONCOLOGY A/S The open-label PANTAX phase Ib international multi-center trial has evaluated Scandion’s lead compound SCO-101 in combination with standard of care chemotherapies gemcitabine and nab-paclitaxel in patients with advanced pancreatic cancer. The majority of the 22 enrolled patients in the study were heavily pretreated and, in those patients, no other active treatment options were available. The data documents long survival in patients with metastatic pancreatic cancer.
“We are encouraged by the positive overall survival data for this hard-to-treat refractory patient population, confirming the top-line results presented last year. These promising data supports the continued development of SCO-101”, says Lars Damstrup, Chief Medical Officer of Scandion.
Overall findings include:
- The maximal tolerated dose (MTD) was established at 200 mg SCO-101 and presented at ESMO 2023
- PK data demonstrated that the exposure of SCO-101 was in line with the expectations
- 15 patients were evaluable for response and 1 had a PR resulting in an ORR of 6.7%
- Amongst the 15 evaluable patients CBR was 53% (1 PR and 7 SD)
- Progression-free survival (PFS) was 2.5 months and overall survival (OS) was 9.5 months. Both are in line with historical data for the same patient population
These final data add to the topline results from PANTAX announced in March and
Evaluation of MTD was the primary endpoint and was found to be 200 mg SCO-101. The clinically meaningful OS of 9.5 months in this very hard to treat malignancy is important as OS is the gold standard in oncology trials and an important regulatory endpoint. Another secondary endpoint in the trial was Progression Free Survival (PFS) and the median was 2.5 months. For both the ORR, OS and PFS the data from the PANTAX are in line with historical data, 3,4,.
References:
1 https://storage.mfn.se/8a2b68af-9360-4e9f-b1cd-255284eb4fa1/clinical-safety-data-from-the-pantax-trial-is-presented-at-esmo-congress-2023.pdf
2 https://scandiononcology.com/mfn_news/scandion-oncology-successfully-completes-the-dose-finding-with-lead-compound-sco-101-in-advanced-pancreatic-cancer-patients-pantax-phase-ib-trial/
3 https://europepmc.org/article/pmc/4651133
4 https://pubmed.ncbi.nlm.nih.gov/31146420/
For further information please contact:
Johnny Stilou, CFO
Phone: +45 2960 3532
E-mail: jos@scandiononcology.com
This information is information that
About
Drug resistance remains a massive problem in cancer treatment and in the development of new medicines. Scandion’s lead compound SCO-101 is currently studying metastatic colorectal cancer (mCRC) in its Phase 2 CORIST trial, while the PANTAX Phase 1 program is developing SCO-101 for pancreatic cancer.
Scandion is based in
© Modular Finance, source
